Christine Garabedian knew, for more than two years, what she wanted to do. She described her experience in physicians' offices: "I'd see the reps talking to doctors and I thought, 'That's what I want to do - how come no one lets me do this?' I knew I'd be good at it."
Christine Garabedian knew, for more than two years, what she wanted to do. She described her experience in physicians' offices: "I'd see the reps talking to doctors and I thought, 'That's what I want to do - how come no one lets me do this?' I knew I'd be good at it."
She was right. Now a highly successful representative, Garabedian is celebrating her seven-year anniversary with Knoll this month - and she looks back on her winding road to pharmaceuticals sales wistfully. She studied classical piano, accounting and finally finance in college. With a plan to see the world, she worked as an aide on Capitol Hill, then moved to Tokyo to teach English. When she returned to the States, she knew she wanted to be "out and about," not tied to a desk, and she began to interview with pharmaceutical companies. But with 1991's tight market, Garabedian was passed over for one frustrating reason: "I had no sales experience," she said. Out of the blue, a past contact called about an open position, remembering Garabedian's enthusiasm from a ride-along. "I didn't seek Knoll," Garabedian explained, "I got lucky."
Her "ability to talk to anybody - at all levels," has been one of Garabedian's strengths in the field. She's also developed creative trademarks that range from speaking Japanese in her Japanese-American physician offices to decking herself out in leopard-print accessories (matching the sales aids of one of her products) to handing out California raisins (her father is a raisin producer). Garabedian admitted: "I've got a few different things that make me stand out from other reps."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.